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Abstract We have cloned a novel serpin (raPIT5a) from a rat
pituitary cDNA library which is structurally related to members
of the ovalbumin subfamily of serine protease inhibitors. This
new cDNA encodes a 374-amino acid protein, designated
raPIT5a. raPIT5a was expressed in specific cells in the
intermediate and anterior lobes of the pituitary. Recombinant
raPIT5a was not secreted suggesting raPIT5a functions to
inhibit intracellular proteases. Recombinant raPIT5a formed an
SDS-stable complex with human granzyme B, a serine protease
which induces apoptosis by activating members of the caspase
enzyme family. These data suggest raPIT5a may have a role in
regulating granzyme B or related enzymes and apoptosis in the
pituitary gland.
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1. Introduction
Serine protease inhibitors or serpins are a large family of
proteins which have been identi¢ed from sources as diverse as
viruses and humans. The serpin family includes most of the
protease inhibitors found in blood as well as many other
proteins with unrelated or unknown functions. Members in-
clude K1-proteinase inhibitor (also called K1-antitrypsin), an-
tithrombin, plasminogen activator inhibitor-1 and the cowpox
viral serpin, cytokine response modi¢er A [1^4]. Serpins play a
critical role in the control of proteolysis. K1-Proteinase inhib-
itor is the principal inhibitor of neutrophil elastase [5]. Anti-
thrombin is an inhibitor of most of the serine proteases in-
volved in the blood coagulation cascade [6]. Plasminogen
activator inhibitor-1 inhibits the plasminogen activators
t-PA and u-PA [7^9]. Cytokine response modi¢er A inhibits
interleukin converting enzyme, a cysteine protease identi¢ed
as being important for programmed cell death [10].
Endocrine tissues express a range of serine proteases includ-
ing enzymes involved in the biosynthesis of biologically active
peptides [11], the regulation of cellular responses to biologi-
cally active peptides [12] and ovulation [13]. These proteases
are likely to be regulated by speci¢c inhibitors [14]. The evi-
dent importance of serpins in endocrine physiology led us to
initiate a new research project to identify novel serine protease
inhibitors in the pituitary using a polymerase chain reaction-
based screening strategy. In this study we report the cloning,
sequencing and expression of a new serpin which is related to
the recently identi¢ed ovalbumin subfamily of serpins.
2. Materials and methods
2.1. Cloning and sequence analysis of raPIT5a
Two degenerate oligonucleotide primers were synthesised based on
conserved sequences that bracket the reactive centre residues and other
conserved regions within the carboxy-terminus of serpins. These prim-
ers (sense, 5P-G(CA)(CA)(GA)GTGCCCATGATG-3P ; antisense, 5P-
A(ACGT)(CA)A(GT)GAA(TA)GG(CG)(CT)(GT)GT-3P) were used
to amplify a V400-bp fragment from rat pituitary ¢rst strand
cDNA. The ampli¢ed DNA was subcloned into M13mp18 or
M13mp19, phage from individual recombinants puri¢ed and the insert
DNA ampli¢ed using M13 forward and reverse sequencing primers.
Ampli¢ed DNA was restricted with HinfI and HaeIII. DNAs that
showed unique fragmentation patterns with either enzyme were further
characterised by DNA sequence analysis using an ABI Model 370
DNA sequencer and a unique serpin sequence, named raPIT5a, iden-
ti¢ed. Using this sequence as a probe, a V3.3-kb raPIT5a clone was
isolated from a rat pituitary cDNA library and sequenced in both
directions.
2.2. In situ hybridisation histochemistry
Two RNA probes were prepared to raPIT5a sequences 235^697 and
714^1112 using T7 and T3 RNA polymerase (Ambion, Texas, USA)
and uridine 5P-(K-thio)triphosphate (Dupont NEN, Massachusetts,
USA). Each probe was generated using the polymerase chain reaction
and included T3 and T7 primer sequences at the 5P termini to allow
the preparation of sense and antisense probes. Details of the in situ
hybridisation histochemistry methodology can be found at http://in-
tramural.nimh.nih.gov/lcmr/snge/. Tissue sections were hybridised
with sense and antisense riboprobes encoding either the 5P or 3P probe
sequences. Sections were opposed to Biomax MS ¢lm and then dipped
in NTB3 nuclear track emulsion (Kodak). Sections were exposed to
emulsion for 20 days at 4‡C before development with Kodak Dektol
at 15‡C and counterstaining with cresyl violet. All animals were main-
tained in accordance with the NIH Guide for the Care and Use of
Laboratory Animals.
2.3. Expression and analysis of recombinant raPIT5a
A pGem-raPIT5a construct containing a 2.9-kb raPIT5a BamHI
fragment was used to direct expression of recombinant raPIT5a in
BSC-40 cells using the vaccinia virus/T7 RNA polymerase hybrid
system. A 10-cm dish was seeded with 4U106 BSC-40 cells and in-
fected the following day for 30 min with 4.5U106 PFU vTF7-3 (re-
combinant virus expressing the T7 RNA polymerase gene). The cells
were then incubated overnight with a pGem-raPIT5a/Lipofectamine
suspension (Life Technologies) and after incubation for a further
2 days, cells and media analysed for raPIT5a expression.
To determine whether recombinant raPIT5a was secreted or re-
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mained predominantly inside the cell, media from BSC-40 cells ex-
pressing raPIT5a were concentrated using a Nanospin microconcen-
trator (Gelman Sciences, USA). Cells were homogenised in 20 mM
Tris-HCl, pH 7 at 4‡C. 1/9 of the cell homogenate and 1/25 of the
concentrated culture supernatant were fractionated on 10% SDS-poly-
acrylamide gels under reducing conditions using the bu¡er of Laemm-
li [15] and analysed by Western blotting. Polyclonal antibodies speci¢c
for raPIT5a were raised in rabbits using a raPIT5a-GST fusion pro-
tein immunogen prepared using sense and antisense PCR primers to
sequences 841^860 and 940^957, respectively.
2.4. Complex formation between raPIT5a and granzyme B
raPIT5a was subcloned into pcDNA3.1 (Invitrogen) behind the T7
promoter. Radiolabelled raPIT5a was produced in a coupled TnT
reticulocyte lysate system (Promega) using T7 RNA polymerase and
incorporating [35S]methionine (Amersham). For complex formation
1 Wl of the translation mix was incubated with varying amounts of
human granzyme B in 67 mM Tris-HCl pH 7.6, 133 mM NaCl for 30
min at 37‡C. Samples were separated on 10% SDS-polyacrylamide
gels under reducing conditions using the bu¡er of Laemmli and ana-
lysed using a phosphoimager (Fuji FLA2000) or Western blotting
using a monoclonal antibody speci¢c for granzyme B [16].
3. Results
3.1. Nucleotide and predicted protein sequence of raPIT5a
The coding sequence of the raPIT5a cDNA is shown in Fig.
1. The predicted initiating methionine is located 73 bp from
the 5P end of the DNA and is included in the single open
reading frame of 374 amino acids ending with a termination
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Fig. 1. Nucleotide and predicted protein sequence of raPIT5a. Ar-
rows indicate the sequences which annealed to the degenerate oligo-
nucleotide primers. Potential N-linked glycosylation sequences are
boxed and a potential polyadenylation signal is underlined. A dou-
ble line highlights the sequence used to prepare the glutathione S-
transferase-raPIT5a fusion protein immunogen.
Fig. 2. Distribution of raPIT5a mRNA in the pituitary gland.
Bright¢eld (A) and dark¢eld (B) images of the pituitary gland show-
ing raPIT5a mRNA expression. The posterior (p), intermediate (i)
and anterior (a) lobes are indicated. Arrows indicate selected cells in
the anterior pituitary that are heavily labeled. The bar represents
200 Wm.
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codon at nucleotide positions 1195^1197. raPIT5a lacks a
typical cleavable NH2-terminal signal sequence but contains
two hydrophobic regions near the amino terminus (amino
acid residues 4^16 and 28^44) which are very similar to
PAI-2 and PI-8. In PAI-2 these regions appear to enhance
glycosylation and secretion [17]. A consensus polyadenylation
signal is located at nucleotide positions 3267^3272, 10 bp
before the poly(A) tail. The poly(A) tail supports the cloning
of the complete raPIT5a cDNA and indicates a 3P-untrans-
lated sequence of 1986 nucleotides. The protein has a pre-
dicted molecular mass of 42.3 kDa and potential N-linked
glycosylation sites at Asn8, Asn23, Asn245 and Asn359.
3.2. Cellular distribution of raPIT5a mRNA in the rat pituitary
gland
raPIT5a mRNA was detected in the intermediate and ante-
rior lobes of the pituitary (Fig. 2). Speci¢c cells in the anterior
pituitary were strongly labeled but their peptidergic phenotype
has not been identi¢ed. Melanotropes in the intermediate lobe
showed moderate labeling while no raPIT5a mRNA was de-
tected in the posterior lobe. Identical distributions were seen
with both probes. Sections probed with control sense ribo-
probes showed no labeling (data not shown).
3.3. Expression of recombinant raPIT5a in BSC40 cells
To establish that the raPIT5a cDNA encodes a protein of
the expected size and to determine if it was secreted the
raPIT5a cDNA was expressed in the BSC-40 monkey kidney
cell line. Recombinant raPIT5a protein was detected using a
polyclonal antibody raised against amino acids 257^295 of
raPIT5a expressed as a glutathione S-transferase fusion pro-
tein. A V45-kDa anti-raPIT5a immunoreactive protein was
detected in the cell homogenate of BSC-40 cells transfected
with the raPIT5a cDNA (Fig. 3). No immunoreactive raPIT5a
protein was detected in concentrated culture medium even
after overexposure of the blot (data not shown). No immu-
noreactive protein was detected in cells or concentrated media
that had been infected with vaccinia virus but not transfected
with the raPIT5a cDNA.
3.4. Complexation of raPIT5a with human granzyme B
raPIT5a was expressed using a coupled in vitro transcrip-
tion/translation system. Two major translation products were
seen with molecular masses of V43 and 44.5 kDa. The two
raPIT5a proteins may result from alternative translation ini-
tiation at nucleotides 73 and 124, respectively. Incubation of
raPIT5a with human granzyme B resulted in the formation of
an SDS-stable complex. The composition of the complex was
veri¢ed by the presence of labeled raPIT5a (phosphoimager,
Fig. 4A) and granzyme B (Western blot with an anti-gran-
zyme B monoclonal antibody, Fig. 4B).
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Fig. 3. Expression of recombinant raPIT5a in a monkey kidney cell
line. Recombinant raPIT5a was transiently expressed in BSC-40 cells
using the vaccinia virus/T7 RNA polymerase hybrid expression sys-
tem. Cell lysate and culture medium from these cells and control
cells that had been infected with vaccinia virus but not transfected
with the raPIT5a cDNA expression plasmid were fractionated by
SDS-PAGE and expression of raPIT5a detected by Western blotting
using a raPIT5a-speci¢c polyclonal antibody.
Fig. 4. Interaction between raPIT5a and human granzyme B. SDS-
stable raPIT5a:granzyme B complexes were formed by incubating
radiolabelled raPIT5a with varying amounts of granzyme B. Sam-
ples were separated by SDS-PAGE and detected using a phos-
phoimager (A) or by Western blot analysis with a granzyme B
monoclonal antibody (B).
Fig. 5. Comparison of the reactive centre loop region of raPIT5a with other serpins. The reactive centre loop region of raPIT5a was compared
with the reactive centre domains of human protease inhibitor 8 (hPI-8), human protease inhibitor 9 (hPI-9) and mouse SPI6. Sequences were
aligned using the Genetics Computer Group sequence analysis software (v 6.0). The arrow indicates the putative P1-P1P bond.
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4. Discussion
We have identi¢ed a novel serpin, which is expressed in the
pituitary. Comparison of the predicted coding sequence of
raPIT5a with other protease inhibitors clearly identi¢es it as
a member of the serpin superfamily. raPIT5a shows highest
similarity to the recently cloned serpin cytoplasmic antipro-
teases PI-6 (58% identity, [18]), PI-8 (58% identity, [19]), PI-9
(70% identity, [19,20]) and SPI6 (86% identity, [20]). This
places raPIT5a in the ovalbumin branch of the serpin super-
family. Overexpression of raPIT5a using a vaccinia-based ex-
pression system resulted in high levels of raPIT5a protein but
no detectable secretion. Therefore, with respect to secretion,
raPIT5a is probably more similar to PI-6 which has been
suggested as a prototype for a new class of intracellular ser-
pins [21].
Sequence conservation of the hinge region of the reactive
centre loop of raPIT5a with other inhibitory serpins suggested
raPIT5a has the potential for direct protease inhibition (Fig.
5). From PI7-P8 nine out of the ten amino acids are identical
to the consensus sequence determined for inhibitory serpins
[22]. The hypervariable reactive centre loop of serpins acts as
a pseudosubstrate for the target protease and thus determines
the speci¢city of the inhibitor. The P1 residue is thought to be
an important determinant of inhibitor speci¢city and is also
used as a tool for classi¢cation of serpins. Sequence compar-
isons within the reactive centre loop region of di¡erent serpins
are shown in Fig. 5. Alignment of the raPIT5a reactive centre
loop with PI-8, PI-9 and SPI6 predicts P1-P1P residues as Tyr-
Cys. In these alignments, a conserved cysteine in the reactive
centre P1P position is identical to other putative cytoplasmic
antiprotease enzymes and the viral antiprotease CrmA [18^
20,23]. The most closely related serpins to raPIT5a that
have been functionally characterised are human PI-9 and
mouse SPI6, the latter hypothesised to be the functional ho-
mologue of human PI-9. Both these serpins are expressed in
immune cells and inhibit the cytotoxic lymphocyte granule
serine protease granzyme B. Inhibition requires a glutamic
acid residue in the reactive centre loop[23]. Granzyme B in-
duces apoptosis by activating members of the caspase enzyme
family by cleavage after acidic amino acids [24]. As raPIT5a
also has a glutamic acid in the reactive centre we investigated
a possible interaction between raPIT5a and granzyme B and
found raPIT5a formed an SDS-stable complex with human
granzyme B.
Our results identify raPIT5a as a potential inhibitor of pro-
teases which cleave target substrates following acidic amino
acids. RaPIT5a could inhibit granzyme B or related proteases
that may be expressed in the pituitary. Interleukin converting
enzyme-like proteases, or caspases, which have been impli-
cated in apoptosis [25] are also candidates for inhibition by
raPIT5a. Caspases are synthesised as zymogens and activated
by proteolytic cleavage at speci¢c aspartic acid residues. Re-
cently, similarities between the viral serpin CrmA and intra-
cellular serpins of the ovalbumin subfamily, particularly PI-9,
have been identi¢ed [19] leading to the suggestion that PI-9
and homologues may inhibit apoptotic cysteine proteases
[20,23].
Acknowledgements: We would like to thank Dr Michael Brownstein
(NIH) for providing the rat pituitary cDNA library, Dr Tom Feurst
(NIH) for vTF7-3 and Gyongyi Harta for expert technical help. We
would also like to thank Dr David Christie for critical reading of the
manuscript. This research was supported, in part, by grants from the
Auckland Medical Research Foundation, The University of Auckland
Research Committee and The New Zealand Lotteries Board (Health)
to N.P.B.
References
[1] Travis, J. and Salvesen, G.S. (1983) Annu. Rev. Biochem. 52,
655^709.
[2] Huber, R. and Carrell, R.W. (1989) Biochemistry 28, 8951^8966.
[3] Bode, W. and Huber, R. (1992) Eur. J. Biochem. 204, 433^451.
[4] Potempa, J., Korzus, E. and Travis, J. (1994) J. Biol. Chem. 269,
15957^15960.
[5] Carrell, R.W., Jeppsson, J.O., Laurell, C.B., Brennan, S.O.,
Owen, M.C., Vaughan, L. and Boswell, D.R. (1982) Nature
298, 329^334.
[6] van Boven, H.H. and Lane, D.A. (1997) Semin. Hematol. 34,
188^204.
[7] Erickson, L.A., Ginsberg, M.H. and Loskuto¡, D.J. (1984)
J. Clin. Invest. 74, 1465^1472.
[8] Juhan-Vague, I., Moerman, B., De, C.F., Aillaud, M.F. and
Collen, D. (1984) Thromb. Res. 33, 523^530.
[9] Booth, N.A., Simpson, A.J., Croll, A., Bennett, B. and MacGre-
gor, I.R. (1988) Br. J. Haematol. 70, 327^333.
[10] Ray, C.A., Black, R.A., Kronheim, S.R., Greenstreet, T.A.,
Sleath, P.R., Salvesen, G.S. and Pickup, D.J. (1992) Cell 69,
597^604.
[11] Rouille, Y. et al. (1995) Front. Neuroendocrinol. 16, 322^361.
[12] Friedman, Y., Wilger, J., Crowell, D. and Burke, G. (1983) En-
docrinology 112, 1674^1679.
[13] Reich, R., Miskin, R. and Tsafriri, A. (1985) Endocrinology 116,
516^521.
[14] Hook, V.Y., Azaryan, A.V., Hwang, S.R. and Tezapsidis, N.
(1994) FASEB J. 8, 1269^1278.
[15] Laemmli, U.K. (1970) Nature 227, 680^685.
[16] Trapani, J.A., Browne, K.A., Dawson, M. and Smyth, M.J.
(1993) Biochem. Biophys. Res. Commun. 195, 910^920.
[17] von Heijne, G., Liljestrom, P., Mikus, P., Andersson, H. and Ny,
T. (1991) J. Biol. Chem. 266, 15240^15243.
[18] Coughlin, P., Sun, J., Cerruti, L., Salem, H.H. and Bird, P.
(1993) Proc. Natl. Acad. Sci. USA 90, 9417^9421.
[19] Sprecher, C.A., Morgenstern, K.A., Mathewes, S., Dahlen, J.R.,
Schrader, S.K., Foster, D.C. and Kisiel, W. (1995) J. Biol. Chem.
270, 29854^29861.
[20] Sun, J.R., Bird, C.H., Sutton, V., Mcdonald, L., Coughlin, P.B.,
Dejong, T.A., Trapani, J.A. and Bird, P.I. (1996) J. Biol. Chem.
271, 27802^27809.
[21] Scott, F.L., Coughlin, P.B., Bird, C., Cerruti, L., Hayman, J.A.
and Bird, P. (1996) J. Biol. Chem. 271, 1605^1612.
[22] Hopkins, P.C. and Whisstock, J. (1994) Science 265, 1893^1894.
[23] Sun, J., Ooms, L., Bird, C.H., Sutton, V.R., Trapani, J.A. and
Bird, P.I. (1997) J. Biol. Chem. 272, 15434^15441.
[24] Poe, M. et al. (1988) J. Biol. Chem. 263, 13215^13222.
[25] Villa, P., Kaufmann, S.H. and Earnshaw, W.C. (1997) Trends
Biochem. Sci. 22, 388^393.
FEBS 21226 7-12-98
R.M. Hill et al./FEBS Letters 440 (1998) 361^364364
